Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 23, 2001

View Archived Issues

SkyePharma serves termination notice on Bioglan for Solaraze

Inex and GSK agree to develop targeted cancer drugs

Battelle to apply delivery technology to GSK compound

Identical twin study results support finasteride for treatment of male pattern hair loss

Celgene and Cornell extend thalidomide/IMiD research partnership

Cancer therapeutics targeting G-quadruplexes and c-myc in development at Cyternex

ImmunoGen presents new taxane-based TAPs at recent cancer meeting

Gemin X reports in vivo efficacy for small-molecule, cancer-specific apoptosis inducers

Potential development candidates emerging from Panacea's HAAH-targeted oncology program

Early phase I data for CEA/TRICOM encouraging

LJP-394 equieffective to current immunosuppressive therapy in reducing anti-dsDNA antibodies

Celgene JNK inhibitors beneficial in liver ischemia-reperfusion injury

CPMP recommends approval for Kineret

Tarceva enters new phase III trial in combination with gemcitabine and cisplatin

FDA grants approval for the first birth control patch

Tracleer receives FDA approval for pulmonary arterial hypertension

Pegylation of rMETase significantly prolongs half-life and biological activity

Introgen PTEN gene therapy significantly reduces VSMC proliferation and migration

European application for Alibra withdrawn; company focuses on next-generation products

PharmaMar's ET-743 filed in E.U. for advanced soft tissue sarcoma

Eisai seeks partner for RARalpha-selective compound

Pharmaceutical compositions of rFVIIa designed at Novo Nordisk

Anti-CCR2 antibodies reported in recent patent by Millennium

Thyroid receptor ligands from Pfizer with utility in obesity and diabetes

Nippon Soda presents newest antimicrobial agents

Inhibitors of certain receptor tyrosine kinases in early development at Celltech

Sankyo identifies new CMV protease inhibitor

European patent covers new hydroxamic acid-based MMP inhibitors synthesized at Pfizer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...